Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

BioMarin

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of BioMarin's 2012 metabolic sales performance.

Sarepta soars as FDA clears its muscular dystrophy drug

Sarepta soars as FDA clears its muscular dystrophy drug candidates, including BioMarin's drisapersen and PTC Therapeutics' ataluren. ... in the EU for another exon 51-skipping therapy - BioMarin's now-abandoned drisapersen - could block eteplirsen's approval.

Deal Watch August 2016

Deal Watch August 2016 This high premium and the one for Cynapsys (see below) has led to speculation that other potential target mid cap biotech companies such as Vertex, BioMarin and Alexion could command higher ... The lead product is talazoparib, a PARP inhibitor, bought

Santhera facing long delay for muscular dystrophy drug in US

Santhera facing long delay for muscular dystrophy drug in US In recent months the FDA has rejected BioMarin's exon-skipping therapy Kyndrisa (drisapersen) - which has now been abandoned after also being turned down by the EMA - as well as PTC

BioMarin gives up on muscular dystrophy drug

BioMarin gives up on muscular dystrophy drug Makes ‘difficult but necessary’ decision to abandon exon-skipping therapy Kyndrisa. BioMarin has said it will stop development of its Duchenne muscular dystrophy (DMD) drug Kyndrisa after another regulatory knockback. ... The announcement marks the

Sanofi takeover bid rebuffed by Medivation

Sanofi takeover bid rebuffed by Medivation Meanwhile, Medivation has a well-regarded cancer pipeline headed by PARP inhibitor talazoparib (MDV3800) - licensed from BioMarin - in phase III trials for the treatment of patients with breast cancer whose BRCA

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....
Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...
International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...

Infographics